Novartis to acquire Avidity Biosciences in deal worth $12bn
The acquisition will expand Novartis’ neuroscience pipeline
Read More
Section: Sales
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
Read More
BMS and Bain Capital launch new company to develop immunology therapies
The newly formed company has in-licensed five investigational immunology drugs from BMS
Read More
Merck unveils $3bn cost-cutting plan to support pipeline and new product launches
A new restructuring programme has been approved to support the initiative
Read More
Novartis and Matchpoint enter inflammatory disease partnership worth $1bn
The companies will focus on inflammatory diseases that have been historically difficult to treat
Read More